Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Cytokine Therapies: Novel Approaches for Clinical Indications

Cytokine Therapies: Novel Approaches for Clinical Indications

Thursday, March 26, 2009 - Friday, March 27, 2009

The New York Academy of Sciences

Presented By

Presented by the Food and Drug Administration and the New York Academy of Sciences


Despite outstanding therapeutic promise and sound scientific rationale, most cytokine therapies have largely failed to establish clinical utility. This meeting is designed as a forum to critically assess the factors that are limiting the clinical development of cytokines as therapeutic agents. It will cover the successes and failures of recombinant cytokines as therapeutic agents for treating human diseases, including various cancers and autoimmune diseases, and will provide a forum to review the scientific and clinical basis of both successful and unsuccessful attempts to develop cytokines as therapeutic agents. The goal is to identify areas for improvement and to coordinate, develop and disseminate novel approaches to current scientific hurdles that are limiting the development of many cytokine products.

Topics for discussion will include:

  • Improved methods for identifying disease targets
  • Alternative methods for enhancing and targeting cytokine delivery
  • Physicochemical modification of cytokines to prolong their bioavailability

Scientific Organizing Committee

  • Raymond P. Donnelly, PhD, Food and Drug Administration
  • Amy Rosenberg, MD, Food and Drug Administration
  • Howard Young, PhD, National Cancer Institute
  • Kathy Granger, PhD, The New York Academy of Sciences


Presented by


Presented by


This conference is supported by an educational donation provided by:

Abbott Laboratories
Amgen Inc
Celgene Corporation
Centocor Research and Development, Inc


    PBL InterferonSource

      Media Partners

      Bristish Pharmacological Society
      Journal of Interferon and Cytokine Research
      Nature Immunology
      The Federation of Clinical Immunology Societies
      The International Society for Interferon and Cytokine Research
      The Journal of Clinical Investigation
      The Lancet